ELDRED KARY

Average Profitability
15.99%
Insider Buys Quantity
10
Insider Buys Sum
$46,218.65
Insider Sells Quantity
0
Insider Sells Sum
$0

Insider Activity of ELDRED KARY

According to the SEC Form 4 filings, ELDRED KARY, being in a position of

  1. director at Galectin Therapeutics Inc.,
    оver the last 12 months, has bought 14369 shares for $13,301, and sold 0 shares,
    over all time since 2018-09-25, has bought 24200 shares for $46,219, and sold 0 shares.

The largest purchase of all time was on 2019-05-31 and amounted to 3033 shares of Galectin Therapeutics Inc. for $12,981.

Biography of ELDRED KARY

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
$13,3013100
Sells
$000

Comparison of Insiders on Amount of Buys and Sells

2024-12-24PurchaseGalectin Therapeutics Inc.
GALT
director
13,469
0.0211%
$0.82$11,045+53.46%
2024-10-23PurchaseGalectin Therapeutics Inc.
GALT
director
500
0.0008%
$2.60$1,300-38.66%
2024-07-22PurchaseGalectin Therapeutics Inc.
GALT
director
400
0.0006%
$2.39$956-6.65%
2024-01-16PurchaseGalectin Therapeutics Inc.
GALT
director
500
0.0008%
$1.79$893+37.36%
2024-01-16PurchaseGalectin Therapeutics Inc.
GALT
director
400
0.0008%
$2.39$956+37.36%
2023-07-19PurchaseGalectin Therapeutics Inc.
GALT
director
1,598
0.0028%
$1.79$2,854+16.37%
2023-02-21PurchaseGalectin Therapeutics Inc.
GALT
1,000
0.0017%
$1.59$1,591+10%
2023-01-25PurchaseGalectin Therapeutics Inc.
GALT
director
1,300
0.0022%
$1.11$1,443+60%
2019-05-31PurchaseGalectin Therapeutics Inc.
GALT
director
3,033
0.0064%
$4.28$12,981-23.33%
2018-09-25PurchaseGalectin Therapeutics Inc.
GALT
director
2,000
0.0049%
$6.10$12,200-25.86%
Total: 10
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.